Dr. David Shlaes

JB: A new report in USA Today is certainly looking for readers. The title clearly reflects this: “Not 'if' but 'when': Antibiotic resistance poses an existential threat for modern medicine”

This is both the end and the beginning of an era.  I started writing a book, Antibiotics – The Perfect Storm, in 2009 (it was published in 2010). I began writing the blog at the same time.

I want to discuss the idea of superiority trials for antibiotics and some of the issues that many experienced researchers fail to consider when thinking about this topic. I am grateful to George Drusano for his input here. 

Spoiler alert – get out the anti-depressants.

Recent discussions on the economics of innovation in rapid diagnostic testing for bacterial infections in the hospital setting have inspired me to once again take pen (keyboard) in hand.

I never dreamed this would be possible. Of course, so many things are possible today that I thought were impossible that I’m almost embarrassed to admit it (but I have no pride).

Over the past few months I've been arguing that remdesivir, the only approved drug for SARS-2 infection, was never going to make a meaningful impact on COVID because it is an IV-only drug, meaning that it will only be administered to ver

I thought that this would be a good time to review the various vaccines and therapies being studied to combat the coronavirus pandemic.

# Reprinted with permission from Dr. Shlaes' blog. The original post can be found here.  

This is not the MRSA pandemic, ladies and gentlemen. Let's take a look at the MRSA pandemic. In  US hospitals, even today (latest CDC data is from 2014), 46% of S.